HealthCare.gov has about 6.4 million paying customers who are at risk of losing subsidies in a pending Supreme Court case.» Read More
An intestinal illness called Shigellosis and carried by international travelers is spreading across the U.S., according to the Centers for Disease Control and Prevention.
The new Obamacare enrollment numbers show that you can't fix stupid, says Jake Novak. But wait—he's got an idea.
The government for the first time revealed how many people have signed up for HealthCare.gov plans during a special enrollment period.
A BMW ad featuring a "crazy" lady scaring a couple is drawing heat from a mental health advocacy group that wants the ad yanked.
E-cigarettes may have been marketed as a healthier option to cigarettes, yet, a new report shows that 1 in 5 U.K. teenagers have tried them.
As gene therapy emerges in the biotech industry, one analyst explains why it could be the next billion dollar industry.
A national pharmacists' group has adopted a policy discouraging its members from providing death-penalty drugs.
CNBC's Meg Tirrell reports on health care consolidation and PBM stocks to watch.
Teva said the deal would add a portfolio of drugs for the treatment of central nervous system disorders.
Officials have yet to keep their promise to disclose how many people are signing up during a special Obamacare enrollment season.
The CEO of biotech company Genfit told CNBC that the markets are overreacting to the results of its NASH study.
How many of you who have Obamacare went to the doctor's office more often?
For biotech watchers, it's deja vu all over again. Through Wednesday, the Nasdaq Biotechnology Index dropped 6.9 percent since the close March 20.
The world is facing a serious water crisis. Former NFL star Jack Brewer highlights a couple of companies investing in solutions.
A bipartisan compromise to overhaul Medicare bucks the popular impression that Washington can't accomplish anything at all.
Investors are bailing on biotech stocks at such a rapid pace that it is shocking even some of the most-seasoned traders.
Major pharmaceuticals companies have formed a partnership with Genomics England in the first step towards using genetic data from NHS patients.
Employers have ratcheted up the financial incentives they offer workers to participate in wellness programs to a record this year.
Lower-income earners were much more likely to sign up for HealthCare.gov plans, higher earners were cooler to the Obamacare marketplace.
Susquehanna's Stacey Gilbert thinks biotech could be due for a pullback. She lays out an options strategy to protect your biotech holdings.
Get the best of CNBC in your inbox